Related references
Note: Only part of the references are listed.CYT997 Causes apoptosis in human multiple myeloma
Katherine Monaghan et al.
INVESTIGATIONAL NEW DRUGS (2011)
Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents
T. Sanchez-Perez et al.
CELL DEATH AND DIFFERENTIATION (2010)
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita et al.
CLINICAL CANCER RESEARCH (2010)
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma
Manik Chatterjee et al.
BLOOD (2008)
The potential role of mTOR inhibitors in non-small cell lung cancer
Cesare Gridelli et al.
ONCOLOGIST (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent
B Nicholson et al.
ANTI-CANCER DRUGS (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Vascular targeting agents as cancer therapeutics
PE Thorpe
CLINICAL CANCER RESEARCH (2004)
Vascular-targeting therapies for treatment of malignant disease
DW Siemann et al.
CANCER (2004)
Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe
HY Zhang et al.
NEOPLASIA (2004)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
D Chauhan et al.
BLOOD (2004)
The treatment of multiple myeloma with docetaxel (an ECOG study)
WR Friedenberg et al.
LEUKEMIA RESEARCH (2003)
JunD mediates survival signaling by the JNK signal transduction pathway
JA Lamb et al.
MOLECULAR CELL (2003)
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells
D Chauhan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The biology of the combretastatins as tumour vascular targeting agents
GM Tozer et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2002)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
Mitotic checkpoints: from yeast to cancer
K Wassmann et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2001)
Share Paper
